Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001164
Filing Date
2025-05-09
Accepted
2025-05-09 16:05:40
Documents
52
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20250331x10q.htm   iXBRL 10-Q 562960
2 EX-31.1 enzn-20250331xex31d1.htm EX-31.1 12582
3 EX-32.1 enzn-20250331xex32d1.htm EX-32.1 6166
  Complete submission text file 0001410578-25-001164.txt   2689274

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20250331.xsd EX-101.SCH 27153
5 EX-101.CAL enzn-20250331_cal.xml EX-101.CAL 18587
6 EX-101.DEF enzn-20250331_def.xml EX-101.DEF 84510
7 EX-101.LAB enzn-20250331_lab.xml EX-101.LAB 202751
8 EX-101.PRE enzn-20250331_pre.xml EX-101.PRE 153793
55 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20250331x10q_htm.xml XML 221460
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 25930355
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)